KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Liabilities: 2018-2024

Historic Total Liabilities for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $336.9 million.

  • Adaptive Biotechnologies' Total Liabilities fell 14.50% to $286.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.4 million, marking a year-over-year decrease of 14.50%. This contributed to the annual value of $336.9 million for FY2024, which is 4.52% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Total Liabilities of $336.9 million as of FY2024, which was down 4.52% from $352.9 million recorded in FY2023.
  • Adaptive Biotechnologies' Total Liabilities' 5-year high stood at $392.5 million during FY2022, with a 5-year trough of $319.2 million in FY2021.
  • Over the past 3 years, Adaptive Biotechnologies' median Total Liabilities value was $352.9 million (recorded in 2023), while the average stood at $360.8 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first fell by 14.45% in 2021, then increased by 22.95% in 2022.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' Total Liabilities stood at $373.1 million in 2020, then dropped by 14.45% to $319.2 million in 2021, then rose by 22.95% to $392.5 million in 2022, then dropped by 10.10% to $352.9 million in 2023, then fell by 4.52% to $336.9 million in 2024.